![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Once-Daily Doutegravir + Abacavir/Lamivudine is Superior to Efavirenz/Tenofovir/Emtricitabine in Treatment-Naïve HIV Subjects: 144-Week Results - SINGLE Study (ING114467)
|
|
|
Reported by Jules Levin
54th ICAAC Sept 5-9 2014, Washington DC
K Pappa, PharmD1, A Baumgartenm MD2, F Felizarta, MD3, E Florennce, MD4, J Portilla, MD5, SWalmsley, MD6, C Granier, DESS7, D Wong, MSc1, B Wynne, MD1
![ICAAC1.gif](../images/090814/090814-8/ICAAC1.gif)
![ICAAC2.gif](../images/090814/090814-8/ICAAC2.gif)
![ICAAC3.gif](../images/090814/090814-8/ICAAC3.gif)
![ICAAC4.gif](../images/090814/090814-8/ICAAC4.gif)
![ICAAC5.gif](../images/090814/090814-8/ICAAC5.gif)
![ICAAC6.gif](../images/090814/090814-8/ICAAC6.gif)
![ICAAC7.gif](../images/090814/090814-8/ICAAC7.gif)
![ICAAC8.gif](../images/090814/090814-8/ICAAC8.gif)
![ICAAC9.gif](../images/090814/090814-8/ICAAC9.gif)
![ICAAC10.gif](../images/090814/090814-8/ICAAC10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|